Impact of tumor microenvironment on oncolytic viral therapy

Cytokine and Growth Factor Reviews

Volumn 21, Issue 2-3, 2010, Pages 127-134

  Wojton, Jeffrey ^a   Kaur, Balveen ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Extracellular matrix; Microenvironment; Oncolytic; Stromal cell

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANTINEOPLASTIC AGENT; BETA GALACTOSIDASE; BEVACIZUMAB; CANSTATIN; CILENGITIDE; CISPLATIN; COMPLEMENTARY DNA; CYCLOPHOSPHAMIDE; CYTOKINE; DECORIN; ENDOSTATIN; FIBROBLAST GROWTH FACTOR; HISTONE DEACETYLASE INHIBITOR; INTERFERON; INTERLEUKIN 8; NEUTROPHIL COLLAGENASE; ONCOLYTIC VIRUS; RELAXIN; SHORT HAIRPIN RNA; STAT3 PROTEIN; THALIDOMIDE; THROMBOCYTE FACTOR 4; THROMBOSPONDIN 1; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRICHOSTATIN A; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULOTROPIN; MONOCLONAL ANTIBODY;

ADENOVIRUS; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CELL INFILTRATION; CLINICAL TRIAL; COLON CARCINOMA; CYTOKINE RELEASE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; EXTRACELLULAR MATRIX; GLIOMA; GLIOMA CELL; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS 1; HUMAN; IMMUNOMODULATION; INNATE IMMUNITY; KIDNEY CARCINOMA; LIVER CANCER; LIVER CELL CARCINOMA; LUNG CANCER; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MONOTHERAPY; NASOPHARYNX TUMOR; NERVE SHEATH TUMOR; NONHUMAN; NONVIRAL GENE THERAPY; ONCOLYTIC VIROTHERAPY; PANCREAS CANCER; PERIPHERAL NERVE TUMOR; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; SOLID TUMOR; STOMACH CARCINOMA; SUBCUTANEOUS TISSUE TUMOR; THYROID CANCER; THYROID CARCINOMA; TUMOR; TUMOR VASCULARIZATION; VASCULAR TUMOR; VESICULAR STOMATITIS VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRION; VIRUS CELL INTERACTION; VIRUS INFECTION; VIRUS MUTATION; VIRUS PARTICLE; VIRUS REPLICATION; VIRUS STRAIN; ANIMAL; CHEMISTRY; CLINICAL TRIAL (TOPIC); GENETICS; IMMUNOLOGY; METABOLISM; MULTIMODALITY CANCER THERAPY; NEOPLASMS; PATHOLOGY; PHYSIOLOGY; PROCEDURES;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; EXTRACELLULAR MATRIX; HUMANS; IMMUNITY, INNATE; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; ANTIBODIES, MONOCLONAL, HUMANIZED;

EID: 77953616808     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2010.02.014     Document Type: Review

References (87)

1. Liu T., Galanis E., Kirn D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol 2007, 4:101-117.
2. Kaur B., Cripe T.P., Chiocca E.A. Buy one get one free:" armed viruses for the treatment of cancer cells and their microenvironment. Curr Gene Ther. 2009, 9:341-355.
3. Alvarez-Breckenridge C., Kaur B., Chiocca E.A. Pharmacologic and chemical adjuvants in tumor virotherapy. Chem Rev 2009, 109:3125-3140.
4. Marx J. Cancer biology. All in the stroma: cancer's Cosa Nostra. Science 2008, 320:38-41.
5. Folkman J. Fundamental concepts of the angiogenic process. Curr Mol Med 2003, 3:643-651.
6. Bergers G., Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003, 3:401-410.
7. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
8. Benencia F., Courreges M.C., Conejo-García J.R., Buckanovich R.J., Zhang L., Carroll R.H., et al. Oncolytic HSV exerts direct antiangiogenic activity in ovarian carcinoma. Hum Gene Ther 2005, 16:765-778.
9. Cinatl J., Vaikunth S.S., Currier M.A., Miller S.J., Ripberger M.C., Hsu Y., et al. Multimutated herpes simplex virus g207 is a potent inhibitor of angiogenesis. Neoplasia 2004, 6:725-735.
10. Mahller Y.Y., Michaelis M., Driever P.H., Cinatl J., Hrabeta J., Suhan T., et al. Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model. Mol Ther 2007, 15:279-286.
11. Ikeda Y., Kojima T., Kuroda S., Endo Y., Sakai R., Hioki M., et al. A novel antiangiogenic effect for telomerase-specific virotherapy through host immune system. J Immunol 2009, 182:1763-1769.
12. Frantz S., Vincent K.A., Feron O., Kelly R.A. Innate immunity and angiogenesis. Circ Res 2005, 96:15-26.
13. Aghi M., Rabkin S.D., Martuza R.L. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide. Cancer Res 2007, 67:440-444.
14. Kurozumi K., Hardcastle J., Thakur R., Shroll J., Nowicki M., Otsuki A., et al. Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61. Mol Ther 2008, 16:1382-1391.
15. Shim W.S.N., Ho I.A.W., Wong P.E.H. Angiopoietin: a TIE(d) balance in tumor angiogenesis. Mol Cancer Res 2007, 5:655-665.
16. Babic A.M., Kireeva M.L., Kolesnikova T.V., Lau L.F. CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. Proc Natl Acad Sci USA 1998, 95:6355-6360.
17. Zheng M., Deshpande S., Lee S., Ferrara N., Rouse B.T. Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic stromal keratitis. J Virol 2001, 75:9828-9835.
18. Lee S., Zheng M., Kim B., Rouse B.T. Role of matrix metalloproteinase-9 in angiogenesis caused by ocular infection with herpes simplex virus. J Clin Invest 2002, 110:1105-1111.
19. Biswas P.S., Banerjee K., Kim B., Kinchington P.R., Rouse B.T. Role of inflammatory cytokine-induced cyclooxygenase 2 in the ocular immunopathologic disease herpetic stromal keratitis. J Virol 2005, 79:10589-10600.
20. Huszthy P.C., Immervoll H., Wang J., Goplen D., Miletic H., Eide G.E., et al. Cellular effects of oncolytic viral therapy on the glioblastoma microenvironment. Gene Ther 2010, 17(2):202-216.
21. Breitbach C.J., Paterson J.M., Lemay C.G., Falls T.J., McGuire A., Parato K.A., et al. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol Ther 2007, 15:1686-1693.
22. Kurozumi K., Hardcastle J., Thakur R., Yang M., Christoforidis G., Fulci G., et al. Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J Natl Cancer Inst 2007, 99:1768-1781.
23. Willett C.G., Boucher Y., di Tomaso E., Duda D.G., Munn L.L., Tong R.T., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004, 10:145-147.
24. Libertini S., Iacuzzo I., Perruolo G., Scala S., Ieranò C., Franco R., et al. Bevacizumab increases viral distribution in human anaplastic thyroid carcinoma xenografts and enhances the effects of E1A-defective adenovirus dl922-947. Clin Cancer Res 2008, 14:6505-6514.
25. Guse K., Ranki T., Ala-Opas M., Bono P., Särkioja M., Rajecki M., et al. Treatment of metastatic renal cancer with capsid-modified oncolytic adenoviruses. Mol Cancer Ther 2007, 6:2728-2736.
26. Frentzen A., Yu Y.A., Chen N., Zhang Q., Weibel S., Raab V., et al. Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy. Proc Natl Acad Sci USA 2009, 106:12915-12920.
27. Liu T., Castelo-Branco P., Rabkin S.D., Martuza R.L. Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects. Mol Ther 2008, 16:1041-1047.
28. Cai W., Chen X. Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism. Anticancer Agents Med Chem 2006, 6:407-428.
29. Israyelyan A., Shannon E.J., Baghian A., Kearney M.T., Kousoulas K.G. Thalidomide suppressed the growth of 4T1 cells into solid tumors in Balb/c mice in a combination therapy with the oncolytic fusogenic HSV-1 OncdSyn. Cancer Chemother Pharmacol 2009, 64:1201-1210.
30. Guse K., Diaconu I., Rajecki M., Sloniecka M., Hakkarainen T., Ristimäki A., et al. Ad5/3-9HIF-Delta24-VEGFR-1-Ig, an infectivity enhanced, dual-targeted and antiangiogenic oncolytic adenovirus for kidney cancer treatment. Gene Ther 2010, 16(8):1009-1020.
31. Guse K., Sloniecka M., Diaconu I., Ottolino-Perry K., Tang N., Ng C., et al. Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models. J Virol 2010, 84:856-866.
32. Hardcastle J., Kurozumi K., Dmitrieva N., Sayers M.P., Ahmad S., Waterman P., et al. Enhanced antitumor efficacy of vasculostatin (Vstat120) expressing oncolytic HSV-1. Mol Ther 2010, 18:285-294.
33. Pipiya T., Sauthoff H., Huang Y.Q., Chang B., Cheng J., Heitner S., et al. Hypoxia reduces adenoviral replication in cancer cells by downregulation of viral protein expression. Gene Ther 2005, 12:911-917.
34. Shen B.H., Hermiston T.W. Effect of hypoxia on Ad5 infection, transgene expression and replication. Gene Ther 2005, 12:902-910.
35. Shen B.H., Bauzon M., Hermiston T.W. The effect of hypoxia on the uptake, replication and lytic potential of group B adenovirus type 3 (Ad3) and type 11p (Ad11p). Gene Ther 2006, 13:986-990.
36. Aghi M.K., Liu T., Rabkin S., Martuza R.L. Hypoxia enhances the replication of oncolytic herpes simplex virus. Mol Ther 2009, 17:51-56.
37. Chou J., Roizman B. Herpes simplex virus 1 gamma(1)34.5 gene function, which blocks the host response to infection, maps in the homologous domain of the genes expressed during growth arrest and DNA damage. Proc Natl Acad Sci USA 1994, 91:5247-5251.
38. Haseley A., Alvarez-Breckenridge C., Chaudhury A.R., Kaur B. Advances in oncolytic virus therapy for glioma. Recent Pat CNS Drug Discov 2009, 4:1-13.
39. Adusumilli P.S., Chan M., Chun Y.S., Hezel M., Chou T., Rusch V.W., et al. Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesothelioma. Cancer Biol Ther 2006, 5:48-53.
40. Fasullo M., Burch A.D., Britton A. Hypoxia enhances the replication of oncolytic herpes simplex virus in p53- breast cancer cells. Cell Cycle 2009, 8:2194-2197.
41. Connor J.H., Naczki C., Koumenis C., Lyles D.S. Replication and cytopathic effect of oncolytic vesicular stomatitis virus in hypoxic tumor cells in vitro and in vivo. J Virol 2004, 78:8960-8970.
42. Hardcastle J., Kurozumi K., Chiocca E.A., Kaur B. Oncolytic viruses driven by tumor-specific promoters. Curr Cancer Drug Targets 2007, 7:181-189.
43. Cho W., Seong Y.R., Lee Y.H., Kim M.J., Hwang K., Yoo J., et al. Oncolytic effects of adenovirus mutant capable of replicating in hypoxic and normoxic regions of solid tumor. Mol Ther 2004, 10:938-949.
44. Netti P.A., Berk D.A., Swartz M.A., Grodzinsky A.J., Jain R.K. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res 2000, 60:2497-2503.
45. Vargová L., Homola A., Zámecník J., Tichý M., Benes V., Syková E. Diffusion parameters of the extracellular space in human gliomas. Glia 2003, 42:77-88.
46. Sauthoff H., Hu J., Maca C., Goldman M., Heitner S., Yee H., et al. Intratumoral spread of wild-type adenovirus is limited after local injection of human xenograft tumors: virus persists and spreads systemically at late time points. Hum Gene Ther 2003, 14:425-433.
47. Markert J.M., Liechty P.G., Wang W., Gaston S., Braz E., Karrasch M., et al. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther 2009, 17:199-207.
48. Kuriyama N., Kuriyama H., Julin C.M., Lamborn K., Israel M.A. Pretreatment with protease is a useful experimental strategy for enhancing adenovirus-mediated cancer gene therapy. Hum Gene Ther 2000, 11:2219-2230.
49. Ganesh S., Gonzalez-Edick M., Gibbons D., Van Roey M., Jooss K. Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models. Clin Cancer Res 2008, 14:3933-3941.
50. McKee T.D., Grandi P., Mok W., Alexandrakis G., Insin N., Zimmer J.P., et al. Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res 2006, 66:2509-2513.
51. Cheng J., Sauthoff H., Huang Y., Kutler D.I., Bajwa S., Rom W.N., et al. Human matrix metalloproteinase-8 gene delivery increases the oncolytic activity of a replicating adenovirus. Mol Ther 2007, 15:1982-1990.
52. Kim J., Lee Y., Kim H., Huang J., Yoon A., Yun C. Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy. J Natl Cancer Inst 2006, 98:1482-1493.
53. Choi I., Lee Y., Yoo J.Y., Yoon A., Kim H., Kim D., et al. Effect of decorin on overcoming the extracellular matrix barrier for oncolytic virotherapy. Gene Ther 2010, 17(2):190-201.
54. Randall R.E., Goodbourn S. Interferons viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol 2008, 89:1-47.
55. Haralambieva I., Iankov I., Hasegawa K., Harvey M., Russell S.J., Peng K. Engineering oncolytic measles virus to circumvent the intracellular innate immune response. Mol Ther 2007, 15:588-597.
56. Benencia F., Courrèges M.C., Conejo-García J.R., Mohamed-Hadley A., Zhang L., Buckanovich R.J., et al. HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer. Mol Ther 2005, 12:789-802.
57. Zhang Y., Chirmule N., Gao G.P., Qian R., Croyle M., Joshi B., et al. Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol Ther 2001, 3:697-707.
58. Guidotti L.G., Chisari F.V. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001, 19:65-91.
59. Fulci G., Dmitrieva N., Gianni D., Fontana E.J., Pan X., Lu Y., et al. Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses. Cancer Res 2007, 67:9398-9406.
60. Errington F., Steele L., Prestwich R., Harrington K.J., Pandha H.S., Vidal L., et al. Reovirus activates human dendritic cells to promote innate antitumor immunity. J Immunol 2008, 180:6018-6026.
61. Altomonte J., Wu L., Chen L., Meseck M., Ebert O., García-Sastre A., et al. Exponential enhancement of oncolytic vesicular stomatitis virus potency by vector-mediated suppression of inflammatory responses in vivo. Mol Ther 2008, 16:146-153.
62. Ikeda K., Wakimoto H., Ichikawa T., Jhung S., Hochberg F.H., Louis D.N., et al. Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. J Virol 2000, 74:4765-4775.
63. Lun X.Q., Jang J., Tang N., Deng H., Head R., Bell J.C., et al. Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide. Clin Cancer Res 2009, 15:2777-2788.
64. Fulci G., Breymann L., Gianni D., Kurozomi K., Rhee S.S., Yu J., et al. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci USA 2006, 103:12873-12878.
65. Currier M.A., Gillespie R.A., Sawtell N.M., Mahller Y.Y., Stroup G., Collins M.H., et al. Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide. Mol Ther 2008, 16:879-885.
66. Thomas M.A., Spencer J.F., Toth K., Sagartz J.E., Phillips N.J., Wold W.S.M. Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model. Mol Ther 2008, 16:1665-1673.
67. Kottke T., Thompson J., Diaz R.M., Pulido J., Willmon C., Coffey M., et al. Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2. Clin Cancer Res 2009, 15:561-569.
68. Dispenzieri A., Gertz MA, Greipp PR, Kyle RA, Lacy MQ, Lust JA, et al. Phase I trial of systemic administration of edmonston strain of measles virus, genetically engineered to express NIS, with or without cyclophosphamide, in patients with recurrent or refractory multiple myeloma; 2009). http://clinicaltrials.gov/ct2/show/NCT00450814?term=measles+virus+and+cy clophosphamide&rank=1.
69. Chang H., Paulson M., Holko M., Rice C.M., Williams B.R.G., Marié I., et al. Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity. Proc Natl Acad Sci USA 2004, 101:9578-9583.
70. Nguyên T.L., Abdelbary H., Arguello M., Breitbach C., Leveille S., Diallo J., et al. Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc Natl Acad Sci USA 2008, 105:14981-14986.
71. Otsuki A., Patel A., Kasai K., Suzuki M., Kurozumi K., Chiocca E.A., et al. Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses. Mol Ther 2008, 16:1546-1555.
72. Xiao T., Fan J.K., Huang H.L., Gu J.F., Li L., Liu X.Y. VEGI-armed oncolytic adenovirus inhibits tumor neovascularization and directly induces mitochondria-mediated cancer cell apoptosis. Cell Res 2010, 20(3):367-378.
73. Zhang Z., Zou W., Wang J., Gu J., Dang Y., Li B., et al. Suppression of tumor growth by oncolytic adenovirus-mediated delivery of an antiangiogenic gene, soluble Flt-1. Mol. Ther 2005, 11(4):553-562.
74. Guse K., Diaconu I., Rajecki M., Sloniecka M., Hakkarainen T., Ristimäki A., et al. Ad5/3-9HIF-Delta24-VEGFR-1-Ig, an infectivity enhanced, dual-targeted and antiangiogenic oncolytic adenovirus for kidney cancer treatment. Gene Ther 2009, 16(8):1009-1020.
75. Yoo J.Y., Kim J., Kwon Y., Kim E., Kim N.K., Choi H.J., et al. VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth. Mol. Ther 2007, 15(2):295-302.
76. Kang Y., Shin H., Yoo J.Y., Kim J., Kim J., Yun C. Novel cancer antiangiotherapy using the VEGF promoter-targeted artificial zinc-finger protein and oncolytic adenovirus. Mol. Ther 2008, 16(6):1033-1040.
77. Lamfers M.L.M., Gianni D., Tung C., Idema S., Schagen F.H.E., Carette J.E., et al. Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma. Cancer Res 2005, 65(20):9398-9405.
78. Mahller Y.Y., Vaikunth S.S., Ripberger M.C., Baird W.H., Saeki Y., Cancelas J.A., et al. Tissue inhibitor of metalloproteinase-3 via oncolytic herpesvirus inhibits tumor growth and vascular progenitors. Cancer Res 2008, 68(4):1170-1179.
79. He X., Su C., Wang X., Pan X., Tu Z., Gong Y., et al. E1B-55kD-deleted oncolytic adenovirus armed with canstatin gene yields an enhanced anti-tumor efficacy on pancreatic cancer. Cancer Lett 2009, 285(1):89-98.
80. Mullen J.T., Donahue J.M., Chandrasekhar S., Yoon S.S., Liu W., Ellis L.M., et al. Oncolysis by viral replication and inhibition of angiogenesis by a replication-conditional herpes simplex virus that expresses mouse endostatin. Cancer 2004, 101(4):869-877.
81. Yang C., Lin Y., Lin C., Lu J., Bu X., Tsai Y., et al. Oncolytic herpesvirus with secretable angiostatic proteins in the treatment of human lung cancer cells. Anticancer Res 2005, 25(3B):2049-2054.
82. Su C., Na M., Chen J., Wang X., Liu Y., Wang W., et al. Gene-viral cancer therapy using dual-regulated oncolytic adenovirus with antiangiogenesis gene for increased efficacy. Mol. Cancer Res 2008, 6(4):568-575.
83. Li G., Sham J., Yang J., Su C., Xue H., Chua D., et al. Potent antitumor efficacy of an E1B 55kDa-deficient adenovirus carrying murine endostatin in hepatocellular carcinoma. Int. J. Cancer 2005, 113(4):640-648.
84. Liu T., Zhang T., Fukuhara H., Kuroda T., Todo T., Martuza R.L., et al. Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy. Mol. Ther 2006, 14(6):789-797.
85. Liu T., Zhang T., Fukuhara H., Kuroda T., Todo T., Canron X., et al. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors. Clin. Cancer Res 2006, 12(22):6791-6799.
86. Yoo J.Y., Kim J., Kim J., Huang J., Zhang S.N., Kang Y., et al. Short hairpin RNA-expressing oncolytic adenovirus-mediated inhibition of IL-8: effects on antiangiogenesis and tumor growth inhibition. Gene Ther 2008, 15(9):635-651.
87. Han Z., Hong Z., Chen C., Gao Q., Luo D., Fang Y., et al. A novel oncolytic adenovirus selectively silences the expression of tumor-associated STAT3 and exhibits potent antitumoral activity. Carcinogenesis 2009, 30(12):2014-2022.